NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage
biopharmaceutical company, today announced the pricing of its
previously announced underwritten public offering of 4,761,904
shares of its common stock at a price to the public of $21.00 per share. Gross proceeds to
Protagonist from the offering are expected to be $100 million, before deducting underwriting
discounts and commissions and offering expenses. All of the
shares of common stock are being offered by Protagonist. In
addition, Protagonist has granted the underwriters a 30-day option
to purchase up to 714,285 additional shares of common stock at the
public offering price, less underwriting discounts and
commissions. The offering is expected to close on or about
December 15, 2020, subject to
satisfaction of customary closing conditions.
J.P. Morgan Securities LLC, SVB Leerink LLC, Piper Sandler
& Co. and BMO Capital Markets Corp. are acting as joint
book-running managers for the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC) on December 10, 2020. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering have been filed with the SEC and a final
prospectus supplement and accompanying prospectus related to the
offering will be filed with the SEC and will be available on the
SEC's website, located at www.sec.gov. The offering is being made
only by means of a prospectus supplement and accompanying
prospectus. Copies of the prospectus supplement and the
accompanying prospectus related to the offering may be obtained,
when available, from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone
at (866) 803-9204 or by email at
prospectus-eq_fi@jpmchase.com; from SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at
(800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com;
from Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by
telephone at (800) 747-3924 or by email at prospectus@psc.com; or
from BMO Capital Markets Corp., Attention: Equity Syndicate
Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800)
414-3627 or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding Protagonist's expectations regarding the
completion and timing of the public offering. In some cases, you
can identify these statements by forward-looking words such as
"expect," "will," "may," or the negative or plural of these words
or similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances). These
forward-looking statements are based on Protagonist's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
public offering. There can be no assurance that Protagonist will be
able to complete the public offering on the anticipated terms, or
at all. Additional information concerning these and other risks can
be found in Protagonist's periodic filings with the U.S. Securities
and Exchange Commission, including under the heading "Risk Factors"
contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. Any forward-looking statements that
Protagonist makes in this press release speak only as of the date
of this press release. Except as required by law, Protagonist
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-pricing-of-100-million-public-offering-of-common-stock-301190979.html
SOURCE Protagonist Therapeutics, Inc.